| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
|
Sci Transl Med
|
2014
|
2.82
|
|
2
|
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.
|
Nat Rev Clin Oncol
|
2013
|
2.64
|
|
3
|
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
|
J Leukoc Biol
|
2013
|
1.90
|
|
4
|
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
|
Clin Cancer Res
|
2015
|
1.61
|
|
5
|
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
|
J Clin Oncol
|
2017
|
1.39
|
|
6
|
Trial watch: Oncolytic viruses for cancer therapy.
|
Oncoimmunology
|
2013
|
1.36
|
|
7
|
Cancer immunotherapy: the beginning of the end of cancer?
|
BMC Med
|
2016
|
1.32
|
|
8
|
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
|
J Clin Oncol
|
2016
|
1.32
|
|
9
|
Intratumoral immunization: a new paradigm for cancer therapy.
|
Clin Cancer Res
|
2014
|
1.24
|
|
10
|
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
|
Oncoimmunology
|
2014
|
1.22
|
|
11
|
Checkpoint modulation in melanoma: an update on ipilimumab and future directions.
|
Curr Oncol Rep
|
2013
|
0.94
|
|
12
|
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
|
Viruses
|
2015
|
0.92
|
|
13
|
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
|
Toxins (Basel)
|
2014
|
0.92
|
|
14
|
Updates in Therapy for Advanced Melanoma.
|
Cancers (Basel)
|
2016
|
0.91
|
|
15
|
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses.
|
Mol Ther Methods Clin Dev
|
2016
|
0.86
|
|
16
|
Oncolytic virus therapy: A new era of cancer treatment at dawn.
|
Cancer Sci
|
2016
|
0.86
|
|
17
|
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
|
Viruses
|
2016
|
0.85
|
|
18
|
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
|
Immunotherapy
|
2015
|
0.83
|
|
19
|
Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data.
|
Hum Gene Ther
|
2015
|
0.83
|
|
20
|
Trial Watch-Oncolytic viruses and cancer therapy.
|
Oncoimmunology
|
2015
|
0.83
|
|
21
|
Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints.
|
Curr Opin Virol
|
2015
|
0.82
|
|
22
|
Immunotherapy: Combined immunotherapy--a new standard in metastatic melanoma?
|
Nat Rev Clin Oncol
|
2015
|
0.81
|
|
23
|
Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
|
Oncoimmunology
|
2015
|
0.78
|
|
24
|
Personalized virotherapy in cancer.
|
Aging (Albany NY)
|
2015
|
0.78
|
|
25
|
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
|
J Transl Med
|
2016
|
0.77
|
|
26
|
Developments in Intralesional Therapy for Metastatic Melanoma.
|
Cancer Control
|
2016
|
0.77
|
|
27
|
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.
|
Front Oncol
|
2016
|
0.77
|
|
28
|
Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
|
World J Gastroenterol
|
2016
|
0.77
|
|
29
|
Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy.
|
Oncolytic Virother
|
2015
|
0.76
|
|
30
|
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
|
J Transl Med
|
2016
|
0.76
|
|
31
|
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
|
Cancer Immunol Immunother
|
2017
|
0.75
|
|
32
|
Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes.
|
Oncolytic Virother
|
2016
|
0.75
|
|
33
|
Prime time for immune-checkpoint targeted therapy at ASCO 2015.
|
Oncoimmunology
|
2015
|
0.75
|
|
34
|
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
|
Hum Vaccin Immunother
|
2016
|
0.75
|
|
35
|
Immune-checkpoint blockade: the springboard for immuno-combination therapy.
|
Gene Ther
|
2015
|
0.75
|
|
36
|
The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options.
|
Cancers (Basel)
|
2015
|
0.75
|
|
37
|
Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma.
|
Oncolytic Virother
|
2014
|
0.75
|
|
38
|
Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs.
|
Oncolytic Virother
|
2013
|
0.75
|
|
39
|
Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.
|
Onco Targets Ther
|
2016
|
0.75
|